12,233
Total Claims
$3.4M
Drug Cost
1,593
Beneficiaries
$2,108
Cost/Patient
Peer Comparison vs. 4,479 Interventional Cardiology providers
+100%
Cost per patient vs peers
$2,108 vs $1,054 avg
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 9,180 claims · $238K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 633 | $799K |
| Rivaroxaban | 506 | $530K |
| Sacubitril/Valsartan | 441 | $517K |
| Apixaban | 383 | $397K |
| Evolocumab | 338 | $257K |
| Dapagliflozin Propanediol | 139 | $158K |
| Dronedarone Hcl | 74 | $85K |
| Alirocumab | 113 | $75K |
| Semaglutide | 70 | $70K |
| Ticagrelor | 80 | $62K |
| Tirzepatide | 38 | $43K |
| Ranolazine | 151 | $29K |
| Metoprolol Succinate | 813 | $19K |
| Isosorbide Mononitrate | 751 | $16K |
| Rosuvastatin Calcium | 570 | $13K |
Prescribing Profile
Patient Profile
75
Avg Age
46%
Female
1.56
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About